Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
18 mars 2024 16h30 HE
|
Aptose Biosciences, Inc.
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and
Provide Corporate Update on Tuesday, March 26, 2024
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
26 janv. 2024 08h00 HE
|
Aptose Biosciences, Inc.
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
Aptose to Present at the Cantor Global Healthcare Conference
18 sept. 2023 07h45 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
06 sept. 2023 07h45 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
24 août 2023 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
27 juil. 2023 16h04 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 27, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted...
Aptose Presents Highlights from Clinical Update
10 juin 2023 12h00 HE
|
Aptose Biosciences, Inc.
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat...
Aptose Reports Results for the First Quarter 2023
08 mai 2023 16h01 HE
|
Aptose Biosciences, Inc.
─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet...
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
10 avr. 2023 16h01 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
10 mars 2023 18h44 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly...